Navigation Links
Portola Pharmaceuticals to Host Conference Call at 11:00 a.m. Eastern Time Tomorrow to Discuss Betrixaban Partnership and Provide Corporate Update
Date:7/8/2009

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced that it will hold a teleconference at 11:00 a.m. Eastern Time tomorrow, Thursday, July 9, to discuss its second major global partnership deal in the past six months, this time for betrixaban, the company's investigational oral Factor Xa inhibitor anticoagulant currently in Phase II clinical development for the prevention of stroke in patients with atrial fibrillation (SPAF). The company also will provide an update on its pipeline and corporate strategy.

Teleconference Details

To participate in the live call on Thursday, July 9, at 11:00 a.m. Eastern Time, please dial 866-454-4208 from the United States or +1-913-312-1266 internationally. The call will be available as a replay for the next two weeks under the News and Events section of Portola's Web site. To access the replay, please dial 888-203-1112 from the United States or +1-719-457-0820 internationally. The passcode for the replay is 5053448.

About Betrixaban

Betrixaban is an oral Factor Xa inhibitor that has been specifically designed for chronic, once-a-day treatment with a long half-life. Betrixaban is minimally excreted through the kidneys and is the only new oral anticoagulant currently being studied in patients with severe and moderate renal impairment without dose adjustment. As a result, it has the potential to become the only novel oral anticoagulant available for patients with severe renal disease. In addition, betrixaban is not extensively metabolized by cytochrome P450, which may result in reduced potential for drug-drug interactions.

Portola is currently conducting EXPLORE-Xa, a Phase II dose-ranging clinical trial evaluating betrixaban for stroke prevention in 500 patients with atrial fibrillation (SPAF), which is scheduled to be fully enrolled by the end of 2009.

In addition t
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness Celebration ... Conference Center in Chesapeake, Virginia. Each year, ARDX celebrates ... in the Hampton Roads region. The 2015 Women’s History ... Women grow stronger through sharing their stories and learning the ... WWC™ theme is T-talk where we will share a cup ...
(Date:3/28/2015)... 2015 Servpro of Paso Robles ... released a report about the link between mold and ... and according to recent medical research, may even cause ... the Environmental Protection Agency, people with sensitivity to mold ... mold may trigger asthma attacks for asthma sufferers. The ...
(Date:3/27/2015)... Miami, FL (PRWEB) March 27, 2015 ... relationship guide from dating experts Samantha Sanderson and Jason ... a frenzied buzz of media attention. The commotion surrounding ... Sean Roman, prompting him to publish an in-depth review ... emotionally devastated when the men in their lives suddenly ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 In her mid-forties ... prevented her from working, Monica K. arrived at JET ... mending department quiet, defensive and scared. The owners and staff ... Support Services (EPSS) to offer jobs to challenged residents ... patience and a willingness to begin with the end in ...
(Date:3/27/2015)... York (PRWEB) March 27, 2015 The ... ) that allege the statin medication increases the risk ... granted Pfizer Inc.’s Motion to Dismiss four individual cases ... a Case Management Order issued in the U.S. District ... Court determined that the dismissals were warranted because the ...
Breaking Medicine News(10 mins):Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3
... But sites devoted to complementary or alternative medicine may ... 11 (HealthDay News) -- Just 5 percent of Web ... pages focused on complementary or alternative medicine are 15 ... other false information, a new study says. , Moreover, ...
... DC When the public considers competing arguments about a ... agree with the expert whose values are closest to their ... will hold true for nanotechnology, a key study has found. ... today by the Project on Emerging Nanotechnologies (PEN). The study ...
... ... - $352 Average Patient Charge (APC) ... - $13.9 Million EBITDA From Continuing Operations ... 2008 Guidance, SCOTTSDALE, Ariz., Feb. 11 Rural/Metro,Corporation (Nasdaq: RURL ), a leading provider ...
... National Insurers Bring Programs to the State, While ... According to a New Report from HealthLeaders-InterStudy, ... of managed care market intelligence, reports that pay-for-,performance ... According to the,latest Arizona Health Plan Analysis, the ...
... recent years, increasing attention,has been paid to the ... In some instances, proponents of LBA made,overly-optimistic claims ... predictor in,the underwriting process. Milliman expert Jonathan Shreve, ... effective use of Lifestyle-Based,Analytics as an advance in ...
... SAN JUAN, Puerto Rico, Feb. 11 Triple-S,Management Corporation ... in,Puerto Rico, today announced record consolidated operating income of ... $2.15 for the year ended,December 31, 2007 (including $0.07 ... Company,s strong market position and medical cost,management., ...
Cached Medicine News:Health News:Most Breast Cancer Web Pages Contain Reliable Information 2Health News:Nanotechnology's future depends on who the public trusts 2Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 2Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 3Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 4Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 5Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 6Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 7Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 8Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 9Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 10Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 11Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 12Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 13Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 14Health News:Rural/Metro Announces Results for Fiscal 2008 Second Quarter 15Health News:Pay-For-Performance Not Getting a Red-Carpet Reception in Arizona 2Health News:Milliman Expert Addresses Practical Applications of Lifestyle-Based Analytics in Risk Selection 2Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 2Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 3Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 4Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 5Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 6Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 7Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 8Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 9Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 10Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 11Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 12Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 13
(Date:3/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... issuance of an aggregate of 30,000 stock options to ... of 120,500 stock options to employees and consultants of ... years and will be exercisable for a period of ... stock option. About Covalon Covalon Technologies ...
(Date:3/27/2015)... - Medicure Inc. (the "Company") (TSXV:MPH, OTCQB:MCUJF) announces today ... of an aggregate of 236,070 options to certain directors, ... Company pursuant to the Company,s Stock Option Plan. Of ... tenth anniversary of the date of grant, 5,000 are ... date of grant and 50,000 are set to expire ...
(Date:3/27/2015)... , March 27, 2015  Holographic Optical Technologies of ... field of holographic medical imaging, is entering the world ... campaign. Launching on April 20 th , 2015, the ... Pro. The 8-inch and 22-inch displays will allow consumers ... the first time. In addition to the two displays, ...
Breaking Medicine Technology:Covalon Announces Issuance of Stock Options 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... 28, 2011 Shire plc , (LSE: SHP, Nasdaq: ... announced that the US Food and Drug Administration (FDA) approved ... as adjunctive therapy to stimulants for the treatment of attention ... to 17 as part of a total treatment program. The ...
... Feb. 28, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... preliminary clinical data from its Phase 1 trial (SB-728-902). ... subjects who are currently on highly active antiretroviral therapy ... CD4+ T-cell counts.  The study is designed to evaluate ...
Cached Medicine Technology:FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 2FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 3FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 4FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 5FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 6Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 2Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 3Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 4Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 5Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 6
Designed by a neonatalogist to reduce the number of steps required to suction meconium from the infants trachea when seconds count. Meconium suction system optimizes patient and provider safety....
... KIMBERLY-CLARK BALLARD Neonatal ... Elbow is designed for ... of elbow design provide ... lavage/irrigation port and locking ...
KIMBERLY-CLARK BALLARD Neonatal and Pediatric TRACH CARE Y features lavage/irrigation port and locking thumb port. Multiple French sizes and packaging configurations. Gamma sterilized....
... PVC siliconized. Stainless steel spiral reinforced. X-ray opaque ... use. Adjustable Flange: The flange can be adjusted ... of the cervical soft tissue. The lock ring ... connected to the shaft. Maximum Patient Comfort: The ...
Medicine Products: